major depressive disordered i jawza f. al-sabhan, msc. college of pharmacy clinical pharmacy...
TRANSCRIPT
![Page 1: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/1.jpg)
Major Depressive Disordered I
Jawza F. Al-Sabhan, Msc. College of Pharmacy
Clinical Pharmacy Department
Mood Disorder
![Page 2: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/2.jpg)
IntroductionEveryone experiences variations in mood, blues that come and go, disappointments, the normal grief that accompanies the loss of someone you love. But a severe or prolonged depression that interferes with the ability to function or feel pleasure is not a mere
case of the blues. It is an illness.
Depression affects many people of all ages.
It is the 8th leading cause of death for males, and 19th leading cause of death for females.
![Page 3: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/3.jpg)
Epidemiology
Lifetime incidence of depression is 13-20%.
Life time incidence of depression in KSA 17%.
Life time prevalence 5-12%(US,Europe)
Most common age is late 20s.
![Page 4: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/4.jpg)
![Page 5: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/5.jpg)
Pathophysiology hypotheses
Biogenic amine1. Central nervous system (CNS) deficiency in dopamine,
norepinephrine, and/or serotonin
2. Based on knowledge that antidepressants increase monoamine neurotransmission
PermissiveAn underlying deficiency of serotonin accompanied by
decreased noradrenergic transmission
![Page 6: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/6.jpg)
Pathophysiology hypotheses
Neuroendocrine finding 1. Pituitary and adrenal glands are enlarged in depressed
patients, and hypothalamic function may be abnormal.
2. Serotonin exerts a strong influence on HPA axis.
3. Approximately 45% to 60% of patients with major depression have a neuroendocrine abnormality, including hypersecretion of cortisol
![Page 7: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/7.jpg)
NORADRENERGIC TRACTS
Noradrenaline, a key neurotransmitter involved in the control of mood and emotional behavior, is believed to inhibit or stimulate a variety of emotional responses such as anxiety, aggression, stress, and sleep
![Page 8: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/8.jpg)
SEROTONERGIC TRACTS
Serotonin is involved in the regulation of pain, pleasure, anxiety, panic, appetite , and sleep behavior (the sleep-wake cycle).
![Page 9: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/9.jpg)
Risk factors
1. Family history of depressiona. 1st degree relative of patients with depression are 1.5 to 3 times
more likely to develop depressionb. Twin studies
• Monozygotic twins have a 65% concordance rate for depression
• Dizygotic twins have a 14% concordance rate for depression
2. Female gender3. Previous depressive episode4. Chronic medical illness5. Substance abuse
![Page 10: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/10.jpg)
![Page 11: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/11.jpg)
Diagnostic Criteria (DSM-IV)for MDD
1. At least 5 symptoms present for 2 weeks most of day nearly every day2. Represents change from previous functioning
a. Depressed mood*b. Loss of interest or pleasure*c. Appetite or weight changed. Sleep disturbancee. Psychomotor agitation/retardationf. Fatigue/loss of energyg. Feelings of worthlessness/guilth. Decreased concentration/indecisivenessi. Recurrent thoughts of death/suicidal ideation/suicide attempt
3. Symptoms cause social or occupational impairment4. Symptoms are not due to substance abuse or medical condition5. Symptoms are not due to gereavement
![Page 12: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/12.jpg)
Depression Sub-classification
A-Melancholia (endogenous)1. Weight loss2. Early morning awakening3. Extreme listlessness4. Intense guilt5. Inability to cheer up even for a
moment
B- Psychotic (or delusional)1. Mood congruent2. Poverty, physical illness,
moral transgressions3. Occur in 10–25%
C-Atypical depression (exogenous)1. Increased appetite2. Weight gain3. Excessive sleep4. Leaden sensation in the arms
and legs5. Mood reactive
D-Postpartum Depression1. Onset of depression
within 4 weeks2. occurs in 10% to 26%
![Page 13: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/13.jpg)
Specific features of diagnosis
1) Milda) Minimum requirement to make diagnosisb) Minor functional impairment
2) Moderatea) Greater degree of functional impairment
3) Severea) Marked interference with social and/or occupational
functioningb) Suicidal ideation
![Page 14: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/14.jpg)
Assessing Depression
Rating scales
Hospitalization Prognosis
Laboratory studies
Target symptoms
Assessing Depression
![Page 15: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/15.jpg)
Target symptoms
D — depressed moodS — sleepI — interestG — guiltE — energyC — concentrationA — appetiteP — psychomotorS — suicide
![Page 16: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/16.jpg)
Laboratory studies
There are no diagnostic lab tests for depression, although the following should be obtained to rule out other medical illnesses which mimic depression
a. Complete blood count (CBC; i.e., anemia)
b. Thyroid function tests (TFTs; i.e., hypothyroidism)
c. Rapid plasma reagin (RPR; i.e., syphilis)
d. Urine drug screen (i.e., substance abuse)
![Page 17: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/17.jpg)
Prognosis
1. 70% of patients are responsive to antidepressant therapy2. Relapse
a. Following 1st episode, 50% experience another episodeb. Following 2nd episode70% experience another episodec. Following 3nd episode 90% experience another episode
![Page 18: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/18.jpg)
Hospitalization
1. Patients who lack capacity to cooperate with treatment
2. Patients at risk for suicide or other violent behavior
3. Patients who lack psychosocial supports
4. Patients who have other psychiatric or general medical problems.
![Page 19: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/19.jpg)
Rating scales
General purposea. Brief Psychiatric Rating Scale (BPRS), investigator-ratedb. Hopkins Symptom Checklist (SCL-90), patient-rated
Disease-specific rating scales (depression)a. Investigator-rated1) Hamilton Rating Scale for Depression (Ham-D, HRSD)2) Montgomery-Asburg Depression Rating Scale (MADRS)b. Patient-rated1) Beck Depression Inventory (BDI)2) Zung Self Rating Scale
![Page 20: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/20.jpg)
![Page 21: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/21.jpg)
Treatment Goals
![Page 22: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/22.jpg)
Treatment
Electroconvulsive therapy
Medication and
psychotherapy
Medication
Psychotherapy
ChoicesOf
Treatment
![Page 23: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/23.jpg)
Choices of Treatment
Psychotherapy
a. Less severe
b. Less chronic
c. No psychotic
d. Past positive response
e. Medical contraindication to medications
Medication
a. More severe
b. Chronic
c. Recurrent
d. Psychotic
e. Melancholic
f. Past positive response
g. Family history
h. Failure to respond to psychotherapy
![Page 24: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/24.jpg)
Choices of Treatment
Medication and psychotherapy
a. More severe
b. Chronic
c. Partial response to either therapy alone
d. Personality disorder
Electroconvulsive therapy
a. Psychotic
b. Severe or extremely severe
c. Past positive response
d. Failure of several medications or combined treatment trials
e. Need for rapid response
f. Medical contraindications to medications
![Page 25: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/25.jpg)
Antidepressant therapy
Initiation of therapy1. Initiate therapy with divided doses to minimize
adverse drug reactions
2. Consider age of patient and adjust accordingly
3. Target dose should be achieved as quickly as tolerated
4. Improvement in 3–4 weeks of therapy
5. Maximal response in 8 weeks of therapy
![Page 26: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/26.jpg)
Phases of Treatment
Continuation
treatment
Maintenance treatment
Acute
treatment
![Page 27: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/27.jpg)
Acute treatment
1. Duration usually 6–12 weeks2. Response (symptom remission)
a) Definitioni) Complete (> 50% reduction)ii) Partial (> 20% but < 50%)iii) No response (< 20%)
b) Rate of responsei) First week• Decreased anxiety• Improvement in sleep• Improvement in appetiteii) 1–3 weeks• ↑ Activity, sex drive, self-care,
memory• Thinking and movements normalize• Sleeping and eating patterns
normalizeiii) 2–4 weeks• Relief of depressed mood• Less hopeless/helpless• Thoughts of suicide subside
![Page 28: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/28.jpg)
Continuation treatment
1. To prevent relapse
2. Continue antidepressant 6–9 months after 1st episode at same dose
3. Continue with the same treatment and the same dose in acute phase.
![Page 29: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/29.jpg)
Maintenance treatment
1. 1 year duration2. Use full therapeutic doses3. Goal is to prevent new episode (recurrence)4. Potential candidates
a) Three episodes of MDD orb) Two episodes of MDD and:
i) Family history of borderline personality disorder/recurrent MDD in 1st degree relative
ii) Recurrence within 1 year after medicine discontinuediii) Onset before age 20 or after age 60iv) Severe, sudden or life threatening depression
![Page 30: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/30.jpg)
Factors to be consider on Selection of an antidepressant
Neurotransmitter profile family history
Side effect profile potential drug interactions
Patient age
cost
ease of administration (compliance)
Safety profile
![Page 31: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/31.jpg)
Class DrugDoseNo per packCostCost/month
TCAImipramine10 mg 60 tablets 16.80 SR100 mg
84 SR
TCAClopimramine25 mg30 Capsules28 SR100 mg
112 SR
SSRIFluvoxamine100 mg 30 tablets92 SR92 SR
SSRIEscitalopram10 mg 28 tablets117 SR125 SR
SSRICitalopram20 mg 28 tablets122 SR130 SR
SSRIFluoxetine20 mg 28 tablets122 SR462 SR
Novel Duloxetine60 mg 28 Capsules179 SR191 SR
DualMirtazapine30 mg 30 tablets177 SR 265.5 SR
DualVenlafaxine150 mg14 capsules135 SR289 SR
![Page 32: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/32.jpg)
ANTIDEPRESSANT MEDICATION: REVIEW
![Page 33: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/33.jpg)
![Page 34: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/34.jpg)
ANTIDEPRESSANT MEDICATION
Antidepressants can be classified in several ways, including by chemical structure and the presumed mechanism of antidepressant activity.All antidepressants are potentially effective in the treatment of depression, they show similar efficacy when used in adequate dosages.
![Page 35: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/35.jpg)
Antidepressants
1. TCA = Tricyclic Antidepressants
2. MAOI = Mono- Amines Oxides Inhibitor
3. SSRI = Selective Serotonin Reuptake Inhibitor
4. SNRI = Serotonin Reuptake Inhibitor
![Page 36: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/36.jpg)
ANTIDEPRESSANT MEDICATION
![Page 37: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/37.jpg)
ANTIDEPRESSANT MEDICATION
Tricyclics “TCAs”Amitriptyline 50 –300 mg/dayClomipramine 50 –250 mg/dayDoxepin 25 –300 mg/dayTrimipramine 50 –300 mg/day Imipramine 50 –300 mg/dayDesipramine 50 –300 mg/dayNortriptyline 25 –150 mg/dayProtriptyline 10 – 60 mg/day
Tertiary amines
Secondary amines
![Page 38: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/38.jpg)
Mechanism Of Tricyclic Antidepressants TCA
![Page 39: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/39.jpg)
ANTIDEPRESSANT MEDICATION
TricyclicsBlock the reuptake of both norepinephrine (NE) , serotonin (5HT), muscarinic, alpha1 adrenergic, and histaminic receptors.
The extent of these effects vary with each agent resulting in differing side effect profiles.
TCA have effects on cardiac action potentials typical of class IA antiarrhythmics
![Page 40: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/40.jpg)
Possible Adverse Effects of Reuptake Blocking of Antidepressant Drugs*
Serotonin Reuptake Blocking
Nausea, Diarrhea and Gastrointestinal
disturbances (including weight loss early in
treatment, weight gain late in treatment)
Nervousness, Insomnia, Fine tremors
Increase or decrease in anxiety (dose dependent)
Sexual dysfunction (including decreased libido)
Extrapyramidal adverse effects
![Page 41: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/41.jpg)
Possible Adverse Effects of Reuptake Blocking of Antidepressant Drugs*
Nor epinephrine
Reuptake
Blocking
Blurred vision, Dry mouth, Constipation, Urinary retention (Act synergistically with anticholinergics)
Tremors, Increased arousal and Insomnia
Tachycardia
Raised blood pressure
Blockade of antihypertensive effects
![Page 42: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/42.jpg)
Possible Adverse Effects of Receptor Blocking of Antidepressant Drugs*
Blocking
Muscarinic
Receptors
Dry mouth, Constipation, Urinary retention
Sinus tachycardia
Blurred vision
Attack or exacerbation of narrow-angle glaucoma
Cognitive impairment
Memory dysfunction
Blocking
Histamine 1 Receptors
Night-time sedation
Impairment of psychomotor coordination during the
daytime, Drowsiness
Weight gain
Potentiation of central depressant drugs
![Page 43: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/43.jpg)
Tricyclic Antidepressants
Managements of Anticholinergic side effects.
Impaired visual accommodation may be counteracted through the use of pilocarpine eye drops.
Urinary hesitation may be treated by prescribing bethanechol, 200 mg/day
Dry mouth may be counteracted by advising the patient to use sugarless gum or candy or by prescribing an oral rinse of 1% pilocarpine used three or four times daily.
Constipation is best dealt with through adequate hydration and the use of bulk laxatives.
![Page 44: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/44.jpg)
Tricyclic Antidepressants
SedationTCAs also have affinity for histaminergic receptors and produce varying degrees of sedation.
In general, tertiary amines cause greater sedation, whereas secondary amines cause less.
Patients with major depressive disorder with insomnia may benefit from sedation when their medication is given as a single dose before bedtime.
![Page 45: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/45.jpg)
Tricyclic Antidepressants
Weight gain.TCAs have the capacity to induce weight gain possibly through their histaminergic properties.
The degree of weight gain appears to vary by agent (e.g., greater weight gain with amitriptyline and less with desipramine), be dose dependent, and be reversible with cessation of tricyclic antidepressant therapy.
![Page 46: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/46.jpg)
Tricyclic Antidepressants
Neurological effects.TCAs can induce mild myoclonus, this may be a sign of toxicity.
Amoxapine, a TCA with antipsychotic properties, can also cause extrapyramidal side effects and tardive dyskinesia.
In overdoses, tricyclic antidepressants can precipitate seizures especially (Maprotiline).
![Page 47: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/47.jpg)
ANTIDEPRESSANT MEDICATION
Monoamine oxidase irreversible, non
selective inhibitors “MAO Is”Phenelzine 15 –90 mg/day
Tranylcypromine 10 – 60 mg/day
Inhibit the enzymatic breakdown of 5HT and NE.
They are usually reserved for atypical or resistant depression
due to their toxicity profile.
![Page 48: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/48.jpg)
ANTIDEPRESSANT MEDICATION
Reversible monoamine oxidase
inhibitors ”RIMA”Moclobemide
This unique mechanism results in a good tolerability profile and unlike traditional MAOIs, there is no need to restrict dietary tyramine.
![Page 49: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/49.jpg)
Monoamine oxidase inhibitors
Hypertensive crises.A hypertensive crisis can occur when a patient taking an MAOI ingests large amounts of tyramine or other pressor amines in foods or medications.
This reaction is characterized by the acute onset of severe headache, nausea, neck stiffness, palpitations, profuse perspiration, and confusion, possibly leading to stroke and death.
![Page 50: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/50.jpg)
Monoamine oxidase inhibitors
Hypertensive crises.Dietary restrictions include avoiding such foods as aged cheeses or meats, fermented products, yeast extracts
The list of medications that must be avoided includes all sympathomimetic and stimulant drugs as well as over-the-counter decongestants and cold remedies.
![Page 51: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/51.jpg)
![Page 52: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/52.jpg)
Monoamine Oxidase Inhibitors
Cardiovascular effects.Orthostatic hypotension is commonly seen during MAOI treatment.
Possible treatments for this side effect include the addition of salt to increase intravascular volume or use of the steroid fludrocortisone.
MAOI use can also be associated with the development of peripheral edema, which may be helped by the use of support stockings.
![Page 53: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/53.jpg)
Major Depressive Disordered II
Jawza F. Al-Sabhan, Msc. College of Pharmacy
Clinical Pharmacy Department
![Page 54: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/54.jpg)
ANTIDEPRESSANT MEDICATION
![Page 55: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/55.jpg)
COMPARATIVE EFFICACY
SSRIs have a flat dose-response curve. There is seldom any advantage in dosing higher than the usually effective minimum dose.
TCAs, and other atypical antidepressants appear to have an ascending dose-response curve, thus higher doses are usually associated with increased efficacy.
![Page 56: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/56.jpg)
COMPARATIVE SAFETY
Most current literature considers the SSRIs to be better tolerated than TCAs, especially when used at the minimally effective dose.
One meta-analysis has disputed this, arguing that dropout rates (~32%) are not significantly different for either group.
![Page 57: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/57.jpg)
ANTIDEPRESSANT MEDICATION
Selective serotonin reuptake inhibitors “SSRIs”
Fluoxetine 20–40mg/day
Sertraline 50 –200 mg/day
Paroxetine 20–40 mg/day
Fluvoxamine 50 –300 mg/day
Citalopram 20 – 40 mg/day
Escitalopram 10-20 mg/day
![Page 58: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/58.jpg)
Mechanism of SSRI
![Page 59: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/59.jpg)
Possible Adverse Effects of Reuptake Blocking of Antidepressant Drugs*
Serotonin Reuptake Blocking
Nausea, Diarrhea and Gastrointestinal
disturbances (including weight loss early in
treatment, weight gain late in treatment)
Nervousness, Insomnia, Fine tremors
Increase or decrease in anxiety (dose dependent)
Sexual dysfunction (including decreased libido)
Extrapyramidal adverse effects
![Page 60: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/60.jpg)
ANTIDEPRESSANT MEDICATION
Selective Serotonin Reuptake InhibitorsBlock the reuptake of 5HT and increase synaptic 5HT transmission.
They have little or no effect on other neurotransmitters, results in fewer anticholinergic (ACH) and sedative effects.
![Page 61: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/61.jpg)
Selective serotonin reuptake inhibitors
Gastrointestinal.SSRIs cause nausea, vomiting, and diarrhea to a greater extent than tricyclic antidepressant medications.
These adverse events are generally dose dependent and tend to
dissipate over the first few weeks of treatment.
![Page 62: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/62.jpg)
Selective serotonin reuptake inhibitors
Activation/insomnia.
In some patients, SSRIs may precipitate or exacerbate restlessness, agitation, and sleep disturbances.
These side effects often attenuate with time.
Anxiety may be minimized by introducing the agent at a low dose; insomnia may be effectively treated by the addition of trazodone, up to 100 mg at bedtime.
![Page 63: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/63.jpg)
Selective serotonin reuptake inhibitors
Sexual side effects.
loss of erectile or ejaculatory function in men and loss of libido and anorgasmia in both sexes may be complications SSRIs.
Lowering the dose, discontinuing the antidepressant, or substituting another antidepressant such as bupropion
Specific pharmacologic treatments that can be added for arousal or erectile dysfunction include sildenafil, yohimbine.
![Page 64: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/64.jpg)
Selective serotonin reuptake inhibitors
Effects on weight.
Fluoxetine has been shown to cause an initial reduction in weight but this tends be gained back subsequently.
The literature differs as to whether patients taking SSRIs beyond the acute phase do or do not experience weight
gain as a medication side effect.
![Page 65: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/65.jpg)
Selective serotonin reuptake inhibitorsSerotonin syndrome.
SSRI used associated with the rare development of a syndrome due to an excess of serotonergic activity.
Features of serotonin syndrome include:
(abdominal pain, diarrhea, flushing, sweating, hyperthermia, lethargy, mental status changes, tremor and myoclonus, rhabdomyolysis, renal failure, cardiovascular shock, and possibly death.)
it is usually associated with the simultaneous use of multiple serotonergic agents such as SSRIs together with MAOIs.
When patients are being switched from an SSRI with a short half-life to an MAOI, a waiting period of at least 2 weeks is needed between the discontinuation of one medication and the initiation of the other.
When switching from fluoxetine to an MAOI, a waiting period of at least 5 weeks is needed before the MAOI is started.
![Page 66: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/66.jpg)
![Page 67: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/67.jpg)
ANTIDEPRESSANT MEDICATION
Atypical Antidepressants
Norepinephrine-serotonin modulator
Mirtazapine 15 – 45 mg/day
Serotonin-norepinephrine reuptake inhibitors
Venlafaxine 75 –375 mg/day
Dopamine-norepinephrine reuptake inhibitors
Bupropion 150 – 450 mg/day
![Page 68: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/68.jpg)
MIRTAZAPINE
The drug mainly affects serotonin (5-HT) receptors of the 5-HT2 and 5-HT-3 subtypes, possessing low affinity for 5-HT1A, 5-HT1B, and 5-HT1C receptors; as a 5-HT2 antagonist.
mirtazapine has strong alpha-2 receptor blocking actions, but unlike mianserin it has no significant effect on the synaptic reuptake of catecholamines.
![Page 69: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/69.jpg)
MIRTAZIPINE SIDE EFFECTS
The most common side effects from mirtazapine include sedation, dry mouth, and weight gain.
Mirtazapine has also been shown to increase serum cholesterol levels in some patients.
Although agranulocytosis has been observed to occur in patients taking mirtazapine.
![Page 70: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/70.jpg)
VENLAFAXINE
Venlafaxine is selectively inhibits neuronal uptake of serotonin, norepinephrine.
The initial recommended dosage of regular-release venlafaxine is 75 milligrams (mg)/day; the dose may be titrated at 4-day intervals to a maximum dose of 375 mg/day.
Major Side Effect: Hypertension
![Page 71: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/71.jpg)
BUPROPION
Bupropion is a very weak inhibitor of norepinephrine uptake and a weak inhibitor of dopamine uptake.
Side effect including headaches, tremors, and seizures.
![Page 72: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/72.jpg)
DA reuptake
inhibition
Reduce depression Psychomotor activation Antiparkinsonian effects
5HT2
block
Reduce depression Reduce suicidal behavior Antipsychotic effects Hypotension Ejaculatory dysfunction Sedation
NEreuptake
inhibition
Reduce depression Antianxiety effects Tremors Tachycardia Erectile/ejaculatory dysfunction
5HT reuptakeinhibition
Reduce depression Antianxiety effects GI disturbances Sexual dysfunction
Alpha1
block
Postural hypotension Dizziness Reflex tachycardia Memory dysfunction
Anxiety
ACh block
Blurred vision Dry mouth Constipation Sinus tachycardia Urinary retention Cognitive dysfunction
H1
block
Sedation/drowsiness Hypotension Weight gain
AntidepressantAntidepressant
Alpha2
block
Pharmacologic Effects Of Antidepressants
![Page 73: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/73.jpg)
Algorithm for Treatment Major Depressive Disorder.
![Page 74: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/74.jpg)
![Page 75: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/75.jpg)
Electroconvulsive Therapy ECT
MECHANISM OF ECT
Electroconvulsive therapy involves applying a brief electrical pulse to the scalp while the patient is under anesthesia. This pulse excites the brain cells causing them to fire in unison and produces a seizure.
![Page 76: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/76.jpg)
Cont. ECT
Nursing staffPsychiatrist Anesthesiologist
![Page 77: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/77.jpg)
Cont. ECT
Bilateral PlacementRight Unilateral Placement
![Page 78: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/78.jpg)
Comparative Pharmacokinetics
![Page 79: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/79.jpg)
Drug Interactions
Newer antidepressants and CYP P450 inhibitory enzymes
![Page 80: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/80.jpg)
Drug Interactions
TCAsa) TCA + anticoagulant → ↑ anticoagulant effect
b) Enzyme inhibitors → ↑ TCA effect
c) Enzyme inducer → ↓ TCA effect
d) TCA + centrally-acting antihypertensive → ↑ BP
e) TCA + sympathomimetic → ↑ BP plus arrhythmias
f) TCA +MAOI → hypertensive crisis
![Page 81: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/81.jpg)
Drug Interactions
MAOIs
a) MAOI + stimulant → hypertensive crisis
b) MAOI + antidiabetics → hypoglycemia
c) MAOI + insulin → hypoglycemia
d) MAOI + levodopa → hypertensive crisis
![Page 82: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/82.jpg)
Drug Interactions
SSRI a) SSRI + TCA → ↑ TCA effect
b) SSRI + carbamazepine → ↑ carbamazapene
d) SSRI + antipsychotic → ↑ antipsychotic effect
e) SSRI + warfarin → ↑ bleeding time
f) SSRI + MAOI → serotonergic syndrome
![Page 83: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/83.jpg)
![Page 84: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/84.jpg)
Special Populations
Pregnancy
1) Treatmenta) Mild depression—psychotherapy
b) Severe depression with decreased oral intake, suicidality, or psychosis—pharmacotherapy or electroconvulsive therapy (ECT)
2) Antidepressants of choicea) Well-studied during pregnancy (tricyclic antidepressants
[TCAs], fluoxetine)
b) Short-acting (sertraline, paroxetine)
![Page 85: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/85.jpg)
Special populations
Lactation1) Antidepressants of choice
a) Well-studied (?)b) Improved pharmacokinetic profilesc) Limited metabolitesd) Greater receptor selectivity
2) Specific agentsa) Sertraline, paroxetineb) Nortriptyline, desipramine
![Page 86: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/86.jpg)
Special populations
Elderly1. Treatment considerations
a) Pharmacokinetic and pharmacodynamic changesb) Coexisting medical conditions (e.g., cardiovascular disease)c) Anticholinergic side effectsd) Depression-related cognitive dysfunction (pseudo-dementia)
2. Agents of choicea) Short-acting selective serotonin reuptake inhibitors (SSRIs)b) Bupropion
![Page 87: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/87.jpg)
![Page 88: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/88.jpg)
Concurrent medical disorders
Asthmaa) Avoid monoamine oxidase inhibitors (MAOIs) which interfere with
sympathomimetic bronchodilators
Cardiac diseasea) Ventricular arrhythmia, subclinical sinus node dysfunction, conduction
defects
b) Avoid TCAs
c) Use bupropion, SSRIs or ECT
d) MAOIs do not affect cardiac conduction, rhythm, or contraction but may induce orthostasis
![Page 89: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/89.jpg)
Concurrent medical disorders
Dementiaa) Avoid TCAs or antidepressants with
anticholinergic properties
Epilepsya) Avoid bupropion, maprotiline, amoxapine, TCAs
Glaucoma (narrow-angle)a) Avoid TCAs
![Page 90: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/90.jpg)
Concurrent Medical Disorders
Hypertensiona) TCAs may antagonize the therapeutic actions of
guanethidine, clonidine, or methyldopa
c) Concurrent antihypertensive treatment, especially with diuretics, increases likelihood that TCAs, MAOIs, or trazodone will induce orthostasis
d) β-blockers, esp. propranolol may cause depression
Parkinson’s diseasea) Avoid amoxapine (dopamine-receptor blocker)
![Page 91: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/91.jpg)
![Page 92: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/92.jpg)
Patient Education
Treat the patient with the same empathy, respect, and concern that you would treat a patient with a medical illness
Do not be afraid to discuss the symptoms of depression
Be sensitive to the patient’s fear of being stigmatized
Emphasize the common occurrence of depression as well as the many successful treatment options
Compare depression to a common and accepted medical illness (e.g., diabetes or hypertension)
Compare the need for medication compliance with antidepressants to the need for compliance with other maintenance medications (e.g., insulin or antihypertensive agents).
![Page 93: Major Depressive Disordered I Jawza F. Al-Sabhan, Msc. College of Pharmacy Clinical Pharmacy Department Mood Disorder](https://reader036.vdocuments.net/reader036/viewer/2022062517/56649ecb5503460f94bd9469/html5/thumbnails/93.jpg)
Thank god for his mercy,who carry a hope for us with every sunrise!